Chemesis International Inc. Receives Three Additional Cultivation Licenses & Begins Process to Increase Land Package by 10,000 Acres in Colombia
05/29/2019 | 03:06am EDT
VANCOUVER, British Columbia, May 29, 2019 (GLOBE NEWSWIRE) -- Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or “Chemesis”), wholly owned subsidiary La Finca Interacviva-Arachna Med SAS (“La Finca”) announces it has received notification from the Ministry of Justice, that is has received approval for three new cultivation licenses for three additional farms located near Bogota, Colombia.
Currently, the Company has 5 acres planted for its pilot spring harvest and has the ability to expand to over 100 acres once the initial harvest is complete. These new acres, to be planted soon, not only will be focused on producing biomass but will also contribute in expediting the expansion of La Finca`s seed stock, a crucial step in guaranteeing acreage growth is in sync with seed availability.
The Company has also established a non-profit organization with the sole purpose of promoting cannabis cultivation. The Association for the Promotion of Cannabis Cultivation offers a new agricultural model with focus on the inclusion of farming communities such as indigenous, afro-Colombians, agroindustries and other small farmers with technical advice, seed, and a crop purchasing program.
The Association has joined forces with Ricardo Garzon, one of Latin America’s leading experts in the implementation of sustainable projects. Mr. Garzon has worked for several major organizations including the International Development Bank, USAID, The World Bank, the International Finance Corporation and is a recognized expert in the development and structuring of associative models throughout Latin America. The proposed model will be presented to Colombian communities and will allow La Finca to extend its sowing prospects to add an additional 2,000+ farming families and over 10,000 acres within the next three years to its previously announced land package. The Company believes this puts La Finca on the frontline of the transformation of agriculture in Colombia.
“La Finca has made an incredible amount of progress since joining Chemesis, and the addition of these licenses allows La Finca to further establish our cultivation operations,” said CEO of Chemesis, Edgar Montero. “Mr. Garzon is a welcomed addition and brings a wealth of experience to Chemesis’ Latin American team. The Company believes his expertise and relationships will allow Chemesis to expand its operations significantly through the Association for the Promotion of Cannabis Cultivation.”
Furthermore, with the expected increases of biomass production, La Finca will be moving into its 14,000 ft2 facility by the end of fiscal Q4. The space is strategically located near Bogota’s city centre, airport, and near the company's growing operations, which will allow for cost effective transportation. The facility is currently being built out by using GMP compliant protocols for both extraction and finished goods manufacturing.
“A vital part of Chemesis’ long term vision is establishing a GMP certified facility in Latin America. The facility provides Chemesis the ability to add profitability with extraction and finished goods manufacturing. As regions in Latin America establish regulations, Chemesis will continue to maintain its first mover advantage in the markets we operate in.”
Chemesis is also pleased to announce that it has completed three tranches of a private placement (“Private Placement”) for gross aggregate proceeds of CDN $1,050,000. Chemesis issued a total of 567,567 units (“Units”) under the Private Placement, with each Unit comprised of one common share at a price of CDN $1.85 per share and one common share purchase warrant (“Warrants”), and each Warrant exercisable for a period of 60 months at a price of $2.50. No fees were paid on this placement.
On Behalf of The Board of Directors
Edgar Montero CEO and Director
About Chemesis International Inc.
Chemesis International Inc. is a vertically integrated U.S. Multi-State operator with International operations in Puerto Rico, and Colombia.
Chemesis has been quietly trading on the CSE since July 2018, and has been building cultivation, extraction, distribution, and brands in the markets where the Company operates. The Company focuses on prudent capital allocation to ensure it maintains a first mover advantage as it enters new markets is committed to differentiate itself by deploying resources in markets with major opportunities.
Chemesis has facilities in both Puerto Rico and California, and is in the process of constructing a GMP certified facility in Colombia. Chemesis’ Puerto Rico operations are licensed to operate 100,000 ft2 of cultivation, and 35,000 ft2 of manufacturing floor space. The Company is positioned to win additional licenses in highly competitive merit-based US states, and will expand its footprint to ensure it maintains a first mover advantage.
Forward-Looking Information:This news release contains "forward-looking information" within the meaning of applicable securities laws, including in relation to statements regarding the Acquisition, the Buy-Out Transaction, the anticipated benefits of the Acquisition and the Buy-Out Transaction, respectively, the ability to realize any profits or increase to profits from its production facilities the expected size of the CBD market, the Company’s ability to increase production of various cannabidiol products, and generally regarding the business, profitability, products and future of the Company’s business, its product offerings and plans for revenue generation, sales and marketing, including upon completion of the Acquisition and Buy-Out Transaction, respectively. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Acquisition or Buy-Out Transaction, respectively, will not be completed as proposed or at all, that the anticipated benefits of the Acquisition or Buy-Out Transaction, respectively, will not materialize, that its production facilities will not be profitable or increase profitability as expected, that the CBD market will not expand as anticipated, that the Company will not be able to expand production of CBD products at the rate anticipated upon closing of the Acquisition or Buy-Out Transaction, respectively (or at all), and generally that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release